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To assess the attack and incidence rates for influenza 
virus infections, during October 2006–October 2007 we 
prospectively studied 1,190 adult short-term travelers from 
the Netherlands to tropical and subtropical countries. Par-
ticipants donated blood samples before and after travel and 
kept a travel diary. The samples were serologically tested 
for the epidemic strains during the study period. The at-
tack rate for all infections was 7% (86 travelers) and for 
influenza-like illness (ILI), 0.8%. The incidence rate for all 
infections was 8.9 per 100 person-months and for ILI, 0.9%. 
Risk factors for infection were birth in a non-Western coun-
try, age 55–64 years, and ILI. In 15 travelers with fever or 
ILI, influenza virus infection was serologically confirmed; 7 
of these travelers were considered contagious or incubating 
the infection while traveling home. Given the large number 
of travelers to (sub)tropical countries, travel-related infec-
tion most likely contributes to importation and further influ-
enza spread worldwide.
International tourism has increased tremendously, with ≈908 million tourist arrivals at airports worldwide in 
2007 (1). The annual number of travelers from the Nether-
lands to tropical and subtropical countries, in a population 
of ≈16 million persons, doubled from ≈1 million in 1999 to 
≈2 million in 2007 (2). Increased health risks, particularly 
infectious diseases, are associated with travel. Prospective 
studies estimate that up to 64% of short-term travelers expe-
rience an illness related to travel to (sub)tropical countries 
(3–5). In these studies, respiratory tract infections were the 
second most frequent infectious disease contracted during 
travel, with attack rates (ARs) up to 26%; fever affected 
11%–19.9% of travelers while they were abroad (3–6). In-
fluenza is one of the most frequently acquired infectious 
diseases among travelers (7). Respiratory tract infections, 
including influenza in 6% of cases, commonly caused ill-
ness among patients admitted to a tertiary-care hospital af-
ter they returned from travel (8). Among febrile travelers 
examined at hospitals after return, influenza was diagnosed 
in up to 15% (9–11).
The World Health Organization (WHO) estimates that 
≈5%–15% of the worldwide population is affected by sea-
sonal influenza viruses annually (3). Outbreaks of influenza 
associated with travel by air, ship, or train indicate that in-
ternational travelers are at risk for this infection (12–14) 
and may introduce novel strains into domestic populations 
(15,16). Indeed, in Europe in 2009, >29% of all confirmed 
cases of influenza A(H1N1)pdm09 virus were related to 
travel (17). Also, of patients admitted to Tan Tock Seng 
Hospital in Singapore with confirmed influenza A(H1N1) 
infection, 25% had traveled by plane after onset of illness, 
and 15% became ill while traveling (18).
The incubation period for influenza is 1–5 days, with 
adults most infectious from 1 day before symptom onset to 
≈5–7 days after symptom onset. In healthy adults, a wide 
range of symptoms occur, varying from classic influenza 
and mild illness to asymptomatic infection (19). Because 
influenza is highly contagious and has a short incubation 
period, travel probably contributes considerably to the rap-
id spread of the virus (20).
In temperate climates, influenza is seasonal: most influ-
enza activity occurs in winter, in the Northern Hemisphere 
during November–March and in the Southern Hemisphere 
during April–October. In the tropics, however, the destina-
tion of many short-term travelers, influenza virus circulates 
at low levels year-round (21,22).
Prospective research on influenza during travel is 
sparse. To our knowledge, the only prospective study 
that estimated the AR and incidence rate (IR) of influenza 
among travelers was a cohort study conducted during 1998–
2000 (6). This study reported that 1.2% of all travelers had 
a confirmed influenza virus infection, defined as a >4-fold 
increase in antibody titers, and an influenza incidence of 1.0 
per 100 person-months abroad. We prospectively estimated 
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the AR and IR for influenza, risk factors for and proportion 
of symptomatic and asymptomatic travelers, and geograph-
ic areas with particular risk.
Methods
Study Population
Persons attending the travel clinic of the Public Health 
Service Amsterdam during October 2006–October 2007 
were recruited for this prospective study. All immunocom-
petent persons >18 years of age were eligible if they were 
planning to travel for 1–13 weeks to >1 (sub)tropical coun-
tries. We used the definition of the United Nations’ Depart-
ment of Economics and Social Affairs (23) and categorized 
these countries in 6 regions: South America; Central Amer-
ica and Caribbean; Middle, Western, and Northern Africa; 
Southern and Eastern Africa; Southeastern and Eastern 
Asia; and South-central and Western Asia.
All participants were seen by a doctor or nurse who 
specialized in travel medicine. They received vaccina-
tions, a prescription for antimalarial chemoprophylaxis if 
required, and oral and written information about how to 
avoid acquiring travel-related diseases in accordance with 
national guidelines of the Netherlands for travelers’ health 
(24). No additional information was provided about how 
to avoid respiratory infections. Influenza vaccination is not 
routinely advised for healthy travelers (25,26).
Survey Methods
Before departure and 2–6 weeks after return, partici-
pants donated venous blood samples for serologic test-
ing. A standard questionnaire was used before departure 
to collect data on sociodemographic characteristics, travel 
history, and purpose of the travel (tourism, work or educa-
tion, or visiting friends and/or relatives [VFR]). History of 
influenza vaccination was not recorded. Participants were 
given a thermometer and asked to take their temperature if 
they felt feverish. They were also asked to keep a structured 
travel diary by recording itinerary, symptoms of disease 
(such as fever, sore throat, or coughing), and self-treatment 
or involvement of a doctor. Participants made daily diary 
entries from the day they arrived at their destination to 1 
week after their return, to encompass incubation periods of 
acute travel-related infections. After travel, the diary was 
checked for entry gaps and interpretations by a nurse in the 
participant’s presence. The study protocol was approved by 
the Medical Ethics Committee of the Academic Medical 
Center Amsterdam (MEC 06/016).
Laboratory Methods and Case Definition
All blood samples were immediately stored at 6°C. 
Blood samples for serologic testing were centrifuged (Het-
tich Rotixa 50S, APP/407: program 1 [Hettich Rotixa, 
Beverly, MA, USA] 10 min. 3,000 rpm [210 × g]) and 
frozen at −80°C within 24 h until use. Paired serum sam-
ples collected from each study participant before travel 
and after return were tested simultaneously. The serum 
samples were tested for antibodies against influenza vi-
ruses by using the hemagglutination-inhibition (HI) assay, 
which was performed in duplicate according to standard 
methods (27,28) with turkey erythrocytes and 4 hemag-
glutinating units of virus propagated in 11-day-old em-
bryonated chicken eggs. For this purpose, vaccine strains 
IVR-142 (A/Wisconsin/67/05-like [H3N2]), IVR-116 (A/
New Caledonia/20/99-like [H1N1]), B/Malaysia/2506/04, 
and B/Florida/4/06 were used to represent the epidemic 
strains that circulated worldwide during the study period 
(29). Ferret antiserum raised against the respective vac-
cine strains were used as positive controls (mean titers 
for subtype H3N2: 2,560; subtype H1N1: 1,280; strain B/
Malaysia: 480; and strain B/Florida: 1,280). For statisti-
cal analysis, a titer of 5 was arbitrarily assigned to serum 
with a titer <10. Titers were transformed to a logarithmic 
scale, and geometric means were used for further calcu-
lations. Because blood samples were collected 2–6 weeks 
after return of travel, acute influenza virus infections were 
not expected, and therefore virus isolation and PCR were 
not used to detect virus in respiratory tract specimens. Pre-
travel titers of >40 for >1 influenza viruses were defined 
as protective antibody titers. If the posttravel titer for >1 
influenza viruses was >40 and showed a >4-fold increase 
above pretravel titer, we defined it as a (serologically) con-
firmed influenza virus infection. Antibodies to influenza B 
viruses can cross-react and overlap to a certain extent with 
the other influenza B virus.
Fever was registered when participants reported a body 
temperature of >38.0°C or when they recorded fever with-
out temperature. In addition to fever, other clinical symp-
toms were scored as influenza-like illness (ILI) when par-
ticipants recorded fever with a temperature of >38.0°C or 
recorded fever without temperature and a sore throat and/or 
cough according to the WHO definition (30). Participants 
who, in addition to fever, had self-reported “flu” or self-
reported “cold” also were included in the ILI definition.
Data Analysis
Data analysis was performed with SPSS version 
19.0.0.1 (2010; IBM, Somers, NY, USA) and Stata ver-
sion 11 (StataCorp LP, College Station, TX, USA). ARs 
were calculated by dividing the number of study partici-
pants displaying seroconversion for >1 influenza viruses 
(indicating infection) by the total number of participants at 
risk. IRs per 100 person-months were calculated by divid-
ing the number of travelers with confirmed influenza virus 
infections by the total number of travel months in which 
participants were at risk for infection. For travelers with 
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confirmed influenza virus infection, we used half of their 
travel duration; for travelers without confirmed influenza 
virus infection we used their total travel duration. Pearson 
χ2 tests of association were used to compare categorical 
variables between any 2 groups. Relative risks of con-
firmed influenza virus infection were expressed as ratios of 
the IR (IRR). IRRs and 95% CIs were obtained by fitting 
Poisson regression models that predicted the incidence of 
confirmed influenza virus infection according to the vari-
ables sex, age, country of birth, previous travel, purpose of 
travel, travel destination, and fever or ILI as a variable for 
symptoms. The multivariable model included all variables 
in a backward stepwise regression. Participants with any 
missing values were omitted from the regression models. 
We chose the backward stepwise approach to ensure inclu-
sion of variables involved in suppressor effects and thus to 
reduce the risk of making a type II error. A p value <0.05 
was considered statistically significant.
Results
Study Population
Originally, we recruited 1,273 immunocompetent per-
sons who intended to travel to (sub)tropical countries. Of 
these, 83 (7%) were excluded: 23 had their travel arrange-
ments cancelled; 42 were lost to follow-up; and 18 did not 
have enough enough serum collected to perform influen-
za serology. Of the remaining 1,190 persons, 510 (43%) 
were male (Table 1, Appendix, wwwnc.cdc.gov/EID/
article/19/6/11-1864-T1.htm). Median age was 37 years 
(interquartile range [IQR] 28–51 years). Most (966 [81%]) 
previously had visited (sub)tropical countries. Most (1,103 
[93%]) participants were born in a Western country; 1,017 
(86%) traveled for holiday; 100 (8%) traveled for work or 
education, and 73 (6%) were VFR. Median travel duration 
was 21 days (IQR 15–28 days). The most frequently visited 
continent was Asia (46%); 27% traveled to Latin America 
and 24% to Africa.
Median time between first blood sample and travel de-
parture was 24 days ([IQR 12–37 days); median time be-
tween return and second blood sample was 23 days (IQR 
19–27 days). Of all participants, 592 (50%) donated the 
first blood sample, and 493 (41%) donated the second blood 
sample during the influenza season in the Netherlands.
Protective Antibody Titers
Of the 1,190 travelers, 839 (71%) had protective an-
tibody titers; 633 (75%) were positive for A(H3N2), 328 
(39%) for A(H1N1), 307 (37%) for B/Malaysia, and 370 
(44%) for B/Florida (Table 2). Of the 839 travelers with 
protective antibody titers, 243 (29%) were immune to 2 in-
fluenza viruses, 140 (17%) for 3 influenza viruses, and 92 
(11%) for 4 influenza viruses.
Confirmed Influenza Virus Infections
Eighty-six travelers had a confirmed influenza infec-
tion caused by >1 viruses (Table 1). The AR was 7% (95% 
CI 6%–9%). Of these 86 travelers, 72 (84%) were born in 
a Western country; 31 (36%) were male, and 75 (87%) had 
traveled previously. Median age was 43 years (IQR 29–55 
years). The travel destination with the highest AR and IR 
was South-central and Western Asia. The IR for serologi-
cally confirmed influenza virus infection per 100 person-
months was 8.9 (95% CI 7.1–10.9).
Of the 86 participants, 66 (77%) displayed a rise in 
antibody titer against 1 influenza virus; 11 (13%) against 2 
viruses; 4 (5%) against 3 viruses, and 5 (6%) against all 4 
viruses, making a total of 120 recent infections. Of all 120 
confirmed influenza virus infections, 44 (37%) were caused 
by A(H3N2); 29 (24%) by A(H1N1); 23 (19%) by B/Ma-
laysia, and 24 (20%) by B/Florida (Table 2). Twenty-two 
(18%) infections occurred in travelers who had protective 
antibodies against the same strain before travel.
Symptoms
Of the 1,190 travelers, 117 (10%) had fever with a 
median temperature of 38.6°C (range 38.0°C–41.3°C); ill-
ness of 40 (3%) met the definition for ILI. Influenza virus 
infection was confirmed in 15 (13%) of the 117 travelers 
with fever and in 9 (23%) of the 40 travelers with ILI; 6 
travelers had only fever, but their illness did not meet the 
ILI definition.
The AR of symptomatic (ILI) confirmed influenza virus 
infection for all travelers was 0.8% (95% CI 0.4%–1.4%) 
with an IR of 0.9 per 100 person-months (95% CI 1.2–3.2). 
In the analysis of travelers with symptomatic confirmed in-
fluenza virus infection, no determinants were found. For 
none of the 4 viruses did we find an association between 
level of posttravel titer and ILI. Only 1 traveler had protec-
tive antibody titers against all 4 influenza viruses, displayed 
a confirmed A(H3N2) infection, and also displayed ILI. 
This 28-year-old woman was known to have asthma and to 
have been hospitalized and treated for symptoms of asthma 
with acetylcysteïne, salbutamol, and amoxicillin.
Of the 9 travelers with symptomatic confirmed in-
fluenza virus infection, 7 (78%) sought medical attention 
abroad, but aside from the asthmatic woman, no hospital-
izations were recorded. Of the 15 travelers with confirmed 
influenza virus infection with fever or ILI, in 7 (47%) 
symptoms started within 1 week before returning home or 
shortly after return.
Independent Risk Factors for Influenza Virus Infection
Age, country of birth, and ILI were independently as-
sociated with confirmed influenza virus infection (Table 1). 
IRR was significantly higher for persons 55–64 years of 
age (IRR 2.6 (95% CI 1.1–6.1) than for persons <25 years; 
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IRRs were significantly higher for travelers born in an Af-
rican (IRR 3.7 [95% CI 1.4–5.5]) or Latin American (IRR 
3.8 [95% CI 1.9–7.8]) country than for persons born in a 
Western country (IRR 3.8 [95% CI 1.9–7.8]); and IRR was 
significantly higher for travelers with ILI (IRR 2.8 [95% 
CI 1.4–5.5]) than for travelers without ILI. Travel duration 
was not associated with influenza virus infection (Pearson 
χ2, p = 0.808). For none of the 4 viruses did we find signifi-
cant associations between confirmed influenza virus infec-
tion and travel destination.
Discussion
This prospective study with short-term travelers to 
(sub)tropical countries supports earlier studies showing 
that influenza is 1 of the most frequently acquired infec-
tious travel-related diseases (7). The AR for confirmed in-
fluenza virus infections was 8%; the IR 8.9 per 100 person-
months. The AR and IR of symptomatic (ILI) confirmed 
influenza virus infection for all travelers was 0.8% and 0.9 
per 100 person-months, respectively.
The prospective study by Mutsch et al. (6) found 
an AR for infection with a >4-fold increase in antibody 
titers of 1.2% and an incidence of 1.0 per 100 person-
months of travel, lower than the overall AR and IR in our 
study. Mutsch et al. found an AR for symptomatic infec-
tion (defined as fever alone) of 0.9%; in our study, AR 
for confirmed influenza virus infection with fever was 2% 
(95% CI 0.7%–2%), which is broadly similar to results of 
Mutsch et al.
However, comparing these 2 studies is difficult be-
cause of different study methods and circumstances. First, 
the characteristics of the populations differed. Mutsch et al. 
included travelers >12 years of age who had travel duration 
<6 months for almost 3 total influenza seasons, and this 
could have affected the AR and IR. Further, we serologi-
cally tested the entire study population, whereas they tested 
a subgroup of travelers with febrile illness and a matched 
group of travelers without febrile illness, possibly leading 
to an underestimation of influenza infections. They also 
defined a group of probable cases by a 2.0- to 3.9-fold in-
crease in antibody titer. In our study, a >4-fold titer rise 
in antibody was used as serologic evidence for influenza 
infection, which is an accepted threshold in the field (31). 
Both studies showed that participants born in African and 
Latin American countries are more likely to have contract-
ed influenza virus infections during travel (p = 0.029 and 
p<0.001, respectively) than those born in Western coun-
tries. Also, in other studies an association was found be-
tween country of birth and risk for certain other infections 
(8,32,33). Possibly VFR travelers have a higher risk for 
influenza because they tend to have closer contact with the 
local population (8,34,35). The GeoSentinel surveillance 
network (8) showed that VFRs and a trip duration of >30 
days were associated with influenza. In our study and the 
study by Mutsch et al. (6), travel duration was not signifi-
cantly associated with confirmed influenza virus infection 
(p = 0.808). Mutsch et al. found the Indian subcontinent 
to be a higher risk area (6). We also found South-central 
and Western Asia to have the highest AR and IR of all re-
gions (11%; 14.4/100 person-months), although these rates 
did not differ significantly from other destinations. In our 
study, the IRR was significantly higher for persons 55–64 
years of age than for persons <25 years, for which we do 
not have an explanation.
In 3 of the travelers who had confirmed influenza vi-
rus infection with fever or ILI, symptoms started within 
1 week before they returned home; they were thus con-
sidered to be contagious during the flight. In 4 travelers 
who had confirmed influenza virus infection with fever 
or ILI, the symptoms started within 1 week after return. 
These 7 travelers probably imported an influenza virus 
that could spread in the Netherlands. In the tropics, influ-
enza viruses circulate throughout the year (21,22). That 
travel occurs year-round suggests that influenza viruses 
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Table 2. Increase in titer and symptoms of influenza-like illness in 1,190 travelers from the Netherlands to (sub)tropical countries, 
October 2006–October 2007 
Strain, subtype, pretravel titer No. travelers, n = 1,190 Titer >4-fold, no. (%), n = 120* Influenza-like illness, no. (%), n = 11 
A    
H3N2    
<40 557 32 (6) 6 (19) 
>40† 633 12 (2) 1 (8)‡ 
H1N1    
<40 862 24 (3) 1 (4) 
>40† 328 5 (2) 0 
B/Malaysia    
<40 883 20 (2) 2 (10) 
>40† 307 3 (1) 0 
B/Florida    
<40 820 22 (3) 1 (5) 
>40† 370 2 (1) 0 
*>4-fold rise between pretravel and posttravel titer and posttravel titer >40. 
†>40: protective antibodies. 
‡Symptoms probably caused by asthma. 
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are imported continuously and spread to other regions of 
the world. Because 7 of 1,190 travelers in our study could 
have imported influenza virus into the Netherlands, the 
≈2 million travelers from the Netherlands who visit (sub)
tropical countries could theoretically represent ≈12,000 
persons importing influenza viruses annually. Because 
asymptomatic travelers also could be infectious, the num-
ber of travelers who import influenza virus is probably 
underestimated. Indeed, evidence suggests that influenza 
A(H3N2) viruses originate in Southeastern and Eastern 
Asia and are spread continuously, causing epidemics 
worldwide (16).
Only 1 traveler with protective antibody titers to all 4 
influenza viruses had a confirmed subtype H3N2 infection 
and ILI. Although we did not register influenza vaccina-
tion status, protective antibodies in this traveler probably 
resulted from vaccination. This traveler had asthma, and all 
asthma patients are offered free influenza vaccinations by 
their general practitioner annually. The influenza vaccine 
contained the same 4 strains for which we tested. The trav-
eler was hospitalized during travel with asthma symptoms. 
Symptoms could have been part of the asthma spectrum 
and might not have been caused by the influenza virus in-
fection. In that case, none of the participants in our study 
with protective antibody titers had a symptomatic influenza 
virus infection (i.e., all symptomatic infections occurred in 
susceptible travelers) (Table 2). Many travelers had pre-
travel protective antibody titers to >1 influenza viruses, 
which may be explained by a history of infection with in-
fluenza viruses and not by influenza vaccination because, 
in the Netherlands, influenza vaccination is not routinely 
advised for healthy travelers.
Our study has several strengths. The prospective na-
ture of the study enabled an estimation of the AR and IR 
of confirmed influenza virus infection with ILI or fever and 
of asymptomatic confirmed influenza virus infections. The 
daily diary entries, which minimize recall bias, provide a 
good record of symptoms during travel. A high percent-
age (90%) of study participants with fever used the ther-
mometer that was offered before travel to measure their 
body temperature. The HI assay is the method of choice 
for seroepidemiologic surveys because it is relatively easy 
to perform and can be used to detect recent infections us-
ing preconvalescent-phase and convalescent-phase serum 
samples (6,36–38).
Our study also has some limitations. First, because 
blood samples were taken some time before and after 
travel, participants could have been infected with influ-
enza virus in the Netherlands. About half of the follow-up 
time was spent during the influenza season in the Neth-
erlands and not abroad, which might have resulted in an 
overestimation of travel-related influenza. Mutsch et al. 
had the same limitation. In Europe, the 2006–07 influ-
enza season began in November and peaked in January 
and was reported to be generally mild. In the Nether-
lands, the 2006–07 influenza epidemic, with a maximum 
clinical influenza activity of 8.2/10,000 inhabitants/
week, was among the 3 smallest registered since 1969 
(39), suggesting that the number of influenza virus in-
fections contracted in the Netherlands might have been 
low. Because the Southern Hemisphere also had mild in-
fluenza activity during our study period (40), the higher 
incidence of confirmed influenza virus infections in our 
study compared with that of Mutsch et al. is difficult to 
explain, possibly because of differences in the sensitivity 
of the HI assays used. Furthermore, the contribution of 
other infectious diseases to disease symptoms cannot be 
excluded. Although influenza B/Malaysia/2506/04 and B/
Florida/4/06 viruses belong to different lineages, antibod-
ies against these viruses may cross-react to a certain ex-
tent. Therefore, seropositivity to these viruses should not 
be considered independent events. Because we found 120 
infections in 86 travelers, including 23 B/Malaysia and 24 
B/Florida virus infections, possible cross-reactions could 
have led to overestimation of the number of influenza B 
virus infections.
Vaccination of all travelers against influenza has been 
discussed (22). In Canada the Committee to Advise on 
Tropical Medicine and Travel recommends influenza vac-
cination to all healthy travelers. WHO recommends annual 
influenza vaccination only for travelers who have condi-
tions that place them at high risk for complications of in-
fluenza. In the Netherlands, as in many other countries, in-
fluenza vaccination is already recommended for these risk 
groups, irrespective of travel. Because travel is not a risk 
factor for severe disease, we believe that there is no need 
to advise influenza vaccinations to all healthy travelers. In 
case of an influenza pandemic with a new strain, vaccina-
tion could play a role in the control of outbreak, but not in 
the beginning, because a new vaccine will not readily be 
available (22).
In conclusion, short-term travelers to (sub)tropical re-
gions contract influenza regularly, which is probably a ma-
jor factor in the epidemiology of influenza. Fifty percent of 
travelers with symptomatic influenza could have imported 
the virus into the Netherlands. Because travelers often visit 
(sub)tropical regions, where influenza viruses continuously 
circulate, after contracting the disease they become vectors 
that further spread the virus worldwide.
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